Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Next Generation COVID-19 vaccines and boosters;
Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA and decentralized trials;
Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease;
DNA Medicines Platform Technology awareness;
Issues related to medical devices and cybersecurity issues;
Issues related to Transitional Coverages of Emerging Technologies (TCET) and medical devices;
Issues related to funding for Advanced Research Projects Agency for Health
Duration: February 17, 2022
to
present
General Issues: Health Issues , Budget/Appropriations , Medical/Disease Research/Clinical Labs
Spending: about $750,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2022: U.S. Senate, House of Representatives, White House Office, Health & Human Services - Dept of (HHS), Defense - Dept of (DOD), State - Dept of (DOS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cookab Hashemi Chief of Staff, Rep. Ruiz; Chief of Staff, Rep. Speier; Dep. Chief of Staff, Rep. Udall; Special Assistant, Sen. Bayh; Confidential Assistant, USDA; Assistant to Special Assistant to the President, White House Office of Political Affairs
John Allen n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, INOVIO PHARMACEUTICALS, INC. did no lobbying for itself. The report was filed on April 22.
Original Filing: 301571787.xml
4th Quarter, 2023
In Q4, INOVIO PHARMACEUTICALS, INC. did no lobbying for itself. The report was filed on Jan. 18.
Original Filing: 301528077.xml
3rd Quarter, 2023
In Q3, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301516926.xml
Lobbying Issues
Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Next Generation COVID-19 vaccines and boosters;
Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA and decentralized trials;
Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease;
DNA Medicines Platform Technology awareness;
Issues related to medical devices and cybersecurity issues;
Issues related to Transitional Coverages of Emerging Technologies (TCET) and medical devices;
Issues related to funding for Advanced Research Projects Agency for Health
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on July 18, 2023.
Original Filing: 301480684.xml
Lobbying Issues
Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease;
Issues related to the Orphan Drug Act and orphan drug destination;
Issues related to the Orphan Drug Tax Credit;
Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA and decentralized trials;
Issues related to CMS IRA implementation and small biotech exemption;
Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Next Generation COVID-19 vaccines and boosters;
Issues related to ASPR/BARDA and manufacturing of pan-coronavirus vaccines and boosters;
Issues related to Oncology and HPV cancers and other associated diseases;
Issues related to medical devices and cybersecurity issues;
Issues related to Transitional Coverages of Emerging Technologies (TCET) and medical devices;
Issues related to FY2024 Labor, Health and Human Services and Education Annual Appropriations;
DNA Medicines Platform Technology awareness
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301465582.xml
Lobbying Issues
Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease;
Issues related to the Orphan Drug Act and orphan drug destination;
Issues related to the Orphan Drug Tax Credit;
Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA;
Issues related to CMS IRA implementation and small biotech exemption;
Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Next Generation COVID-19 vaccines and boosters;
Issues related to ASPR/BARDA and manufacturing of pan-coronavirus vaccines and boosters;
Issues related to Oncology and HPV cancers and other associated diseases;
DNA Medicines Platform Technology awareness
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301439525.xml
Lobbying Issues
Issues related to COVID-19 research and development, vaccine distribution and manufacturing;
Next Generation COVID-19 vaccines and boosters;
Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters;
Issues related to Oncology and HPV cancers;
Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act;
FY2023 Omnibus Appropriations Act, H.R. 2617;
Issues related to the Prescription Drug User Fee Act (PDUFA);
Issues related to the Medical Device User Fees Amendment (MDUFA IV);
ARPA-H Act, H.R 5585;
Accelerated Approval Integrity Act of 2022, H.R. 6963;
Prevent Pandemic Act, S. 3799;
DNA Medicines awareness
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301415578.xml
Lobbying Issues
Issues related to COVID-19 research and development, vaccine distribution and manufacturing;
Issues related to Oncology and HPV cancers;
Next Generation COVID-19 vaccines and boosters;
Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters;
Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act;
Prescription Drug User Fee Act (PDUFA);
Medical Device User Fees Amendment (MDUFA IV);
ARPA-H Act, H.R 5585;
Accelerated Approval Integrity Act of 2022, H.R. 6963;
Prevent Pandemic Act, S. 3799;
DNA Medicines awareness.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301395640.xml
Lobbying Issues
Issues related to COVID-19 research and development, vaccine distribution and manufacturing;
Issues related to Oncology;
Next Generation COVID-19 vaccines and boosters;
Medicare Part B and HPV;
Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters;
Prescription Drug User Fee Act (PDUFA);
Medical Device User Fees Amendment (MDUFA IV);
ARPA-H Act, H.R 5585;
Accelerated Approval Integrity Act of 2022, H.R. 6963;
Speeding Therapy Access Today (STAT) Act, H.R. 1730;
Prevent Pandemic Act, S. 3799
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2023 appropriations - LHHS, AG/FDA, State, Foreign Ops
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, INOVIO PHARMACEUTICALS, INC. had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301368895.xml
Lobbying Issues
Issues related to COVID-19 research and development, vaccine distribution and manufacturing;
Issues related to Oncology
Next Generation COVID-19 vaccines;
Medicare Part B and HPV;
Orphan Drug Act of 1983
Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673;
Accelerated Approval Integrity Act of 2022, H.R. 6963;
Prescription Drug User Fee Act (PDUFA);
Medical Device User Fees Amendments (MDUFA IV);
Prevent Pandemics Act, S. 3799;
Cures 2.0, H.R. 6000;
Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies
TRIPS Waiver for COVID-19 vaccines and therapies;
Outreach to Colombian Congressional Caucus on COVID-19
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Supplemental Appropriations Act of 2022, H.R. 7007, AG/FDA FY2023 appropriations, State, Foreign Ops FY2023 appropriations; LHHS FY2023 appropriations
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
INOVIO PHARMACEUTICALS, INC. filed a lobbying registration on April 13, 2022 for in-house lobbying efforts, effective Feb. 17, 2022.
Original Filing: 301345436.xml
Issue(s) they said they’d lobby about: Issues related to COVID-19 and other infectious diseases; HPV cancer and other diseases and Oncology/Cancer (Pipeline); funding for HHS agencies such as NIH, NCI, FDA and Global Health Security within the State Department and USAID. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...